A Study of MK-0482 as Monotherapy and in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Solid Tumors (MK-0482-001)

Trial Identifier: 0482-001
Sponsor: MSD
Start Date: June 2019
Primary Completion Date: June 2025
Study Completion Date: June 2025
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

Country Location
Australia, New South Wales Macquarie University, New South Wales, Australia, 2109
Australia, Victoria Melbourne, Victoria, Australia, 3004
Canada, BC Vancouver, BC, Canada, V5Z 4E6
Canada, ON Toronto, ON, Canada, M5G 2M9
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 6900941
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 8420383
Israel, N/A Jerusalem, N/A, Israel, 9112001
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Italy, Milano Milano, Italy, 20141
Italy, Toscana Siena, Toscana, Italy, 53100
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03080
Spain, Barcelona Barcelona, Spain, 08036
United States, MI Detroit, MI, United States, 48202
United States, NJ Hackensack, NJ, United States, 07601
United States, TX San Antonio, TX, United States, 78229